labocyte.varastegan@gmail.com
https://instagram.com/labocyte?utm_medium=copy_link
https://t.me/mlssa_varastegan
جمع آوری مطالب: نگار نشات، نگین نجمی، محمدرضا نادری
صداگذاری: فرناز فرزادمهر، آرمین امین زاده
تدوین: تهمینه رحیمی
دبیر: تهمینه رحیمی
استاد راهنما: دکتر حسین جاوید
منابع:
- Bradley SA, Banach M, Alvarado N, Smokovski I, Bhaskar SMM. Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis. Journal of Diabetes. 2022;14(2): 144-157. doi:10.1111/1753-0407.13243
- Gupta P, Gupta M, KAtoch N, Garg K, Garg B. A Systematic Review and Meta-analysis of Diabetes Associated Mortality in Patients with COVID-19. Int J Endocrinol Metab. 2021 Sep 15;19(4):e113220. doi: 10.5812/ijem.113220. PMID: 35069750; PMCID: PMC8762284.
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021 Jan;12(1):143-157. doi: 10.1007/s13300-020-00981-0. Epub 2020 Dec 15. PMID: 33325008; PMCID: PMC7843845.
- Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, Milicevic Z, Haupt A, Robins DA. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. doi: 10.1210/clinem/dgaa863. PMID: 33236115; PMCID: PMC7823251.
- https://www.medicalnewstoday.com/articles/fda-approves-tirzepatide-a-potent-new-drug-for-type-2-diabetes
